

37\_125646\_0\_IR\_072117\_clinical.txt

From: Cagungun, Nannette  
Sent: Friday, July 21, 2017 3:30 PM  
To: 'narin.ahmed@novartis.com'  
Cc: Manisha.patel@novartis.com; Giordano, Erica  
Subject: FW: Information Request: Tisagenlecleucel -T

Importance: High

Follow Up Flag: Follow up  
Flag Status: Flagged

Our Reference: BL 125646/0

Dear Narin:

I understand Manisha is away.

We have the following information request:

1. Please provide the Unique Subject ID for the subjects on B2205J who received the Novartis CTL019 and those who received the UPenn CTL019 by COB today.

Please let me know if you have any questions.

Sincerely,  
Nannette Cagungun, MS, PD, RAC  
Regulatory Project Manager  
Center for Biologicals Evaluation and Research  
Office of Tissues and Advanced Therapies  
U.S. Food and Drug Administration  
Tel: 240-402-8267  
nannette.cagungun@fda.hhs.gov.

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.

From: Cagungun, Nannette  
Sent: Friday, July 21, 2017 3:20 PM  
To: Manisha.patel@novartis.com  
Cc: Giordano, Erica  
Subject: Information Request

Our Reference: BL 125646/0

Dear Manisha,

Please provide the information below by COB today:

1. Please provide the Unique Subject ID for the subjects on B2205J who received the Novartis CTL019 and those who received the UPenn CTL019.

Thanks and regards,

Nannette

Nannette Cagungun, MS, PD, RAC  
Regulatory Project Manager  
Center for Biologics Evaluation and Research  
Office of Tissues and Advanced Therapies  
U. S. Food and Drug Administration  
Tel: 240-402-8267  
nannette.cagungun@fda.hhs.gov.

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.